Remuneration of Non-Executive Directors and TVR

RNS Number : 8957M

Futura Medical PLC

11 January 2019

 

Remuneration of Non-Executive Directors and Total Voting Rights

11 January 2019

Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, announces the issue of 76,828 new ordinary shares of 0.2 pence each ("Ordinary Shares") in respect of the 2018 remuneration of its Non-Executive Directors.

In accordance with the terms of their service agreements, the Non-Executive Directors receive approximately 30 per cent of their remuneration in the form of Ordinary Shares. For 2018, these were issued at 25.10 pence per share, being the average closing mid-market price of the last 10 trading days of 2017 (as announced via RNS on 2 January 2018).

The 76,828 new ordinary shares shall rank pari passu with the existing issued Ordinary Shares of the Company and have been issued as follows:

Director	Number of Ordinary Shares issued for 2018 remuneration	Total number of ordinary shares held	Percentage of the Company's resulting issued share capital
John Clarke	57,250	256,226	0.13%
Jonathan Freeman	19,578	90,621	0.04%

Application has been made to the London Stock Exchange and it is anticipated that trading of the new ordinary shares will commence on AIM at 8:00am on 16 January 2019.

Immediately following the above issue, the Company will have 204,660,267 ordinary shares in issue, each carrying one voting right. Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is therefore 204,660,267 and this figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

The shares element of the Non-Executive Directors' remuneration for 2019 will be awarded at 6.01 pence per Ordinary Share, being the average closing mid-market price of the last 10 trading days of 2018. The Non-Executive Directors will receive these shares in January 2020.

Further details are contained within the notifications below, made in accordance with Article 19 of the EU Market Abuse Regulation 596/2014. Full details of the Non-Executive Directors' remuneration will be included in the Company's Annual Report & Accounts.

ENDS

For further information please contact:

Futura Medical plc 
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO

Email: [e-mail]
Tel: [phone]

Nominated Adviser and Broker:
N+1 Singer
Aubrey Powell/ Ben Farrow (Corporate Finance)

Tom Salvesen/ Mia Gardner (Corporate Broking)
Tel: [phone]

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Hollie Vile/ Ellie Blackwell

Email: [e-mail]

Tel: [phone]

Notes to editors

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	John Clarke
2	Reason for the notification
a)	Position/status	Director/ PDMR
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Futura Medical plc
b)	LEI	21380053QLT46UNV2303
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 0.2p each GB0033278473
b)	Nature of the transaction	Issue of shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 25.10 pence 57,250
d)	Aggregated information - Aggregated volume - Price	Not applicable
e)	Date of the transaction	11 January 2019
f)	Place of the transaction	Outside of trading venue

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Jonathan Freeman
2	Reason for the notification
a)	Position/status	Director/ PDMR
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Futura Medical plc
b)	LEI	21380053QLT46UNV2303
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 0.2p each GB0033278473
b)	Nature of the transaction	Issue of shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 25.10 pence 19,578
d)	Aggregated information - Aggregated volume - Price	Not applicable
e)	Date of the transaction	11 January 2019
f)	Place of the transaction	Outside of trading venue

 

END

 

 

DSHKMGMMGMRGLZM